ロード中...
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
Inhaled corticosteroid/long-acting β(2)-agonist combination therapy is recommended in chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-bl...
保存先:
| 出版年: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4648608/ https://ncbi.nlm.nih.gov/pubmed/26648706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S93375 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|